Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3215 - TP53 mutation predicts sensitivity to adjuvant gemcitabine in pancreatic cancer: results from the CONKO-001 study


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Translational Research;  Pancreatic Cancer


Marianne Sinn


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


M. Sinn1, J. Budczies2, F. Damm1, P. Lohneis2, R. Schmuck3, D. Treue2, J.K. Striefler1, M. Bahra3, U. Pelzer1, A. Jühling1, H. Bläker2, S. Bischoff1, H. Oettle4, C. Denkert5, H. Riess1, B. Sinn2

Author affiliations

  • 1 Medical Oncology, Charite Universitätsmedizin Berlin, 13353 - Berlin/DE
  • 2 Institute Of Pathology, Charite Universitätsmedizin Berlin, 10117 - Berlin/DE
  • 3 Surgery, Charite Universitätsmedizin Berlin, 13353 - Berlin/DE
  • 4 Hematology/oncology, Medical practice - Helmut Oettle, 88045 - Friedrichshafen/DE
  • 5 Institut Of Pathology, Charite Universtitätsmedizin Berlin, German Cancer Consortium (DKTK) Partner Site Berlin, 13353 - Berlin/DE


Abstract 3215


Pancreatic adenocarcinoma (PDAC) is a molecular heterogeneous disease, but clinically relevant genetic biomarkers are still missing. There are no data from prospective studies after curatively intended surgery and adjuvant chemotherapy so far.


CONKO-001, was a prospective randomized phase III study and investigated the role of adjuvant gemcitabine (Gem) as compared to observation (Obs). Formaline-fixed paraffin-embedded tissue samples of 187 patients (pts) could be collected, of which 97 could be analysed after DNA-extraction by targeted next generation sequencing (NGS), using a predefined sequencing panel including mutation hotspot regions of 36 genes (ACTN4, ACVR1B, APC, ARID1A, ARID1B, ARID2, ATM, BRAF, CDK6, CDKN2A, CNDP2, CREBBP, CTNNB1, ERBB2, FGFR1, GATA6, KDM6A, KMT2C, KMT2D, KRAS, MAP2K4, MET, MYC. PBRM1, PIK3CA, PREX2, RNF43, RPA1, SF3B1, SMAD4, SMARCA2, SMARCA4, SOX9, STK11, TGFBR2, TP53). Mutational status was correlated with survival by fitting a cox proportional hazard model.


Patient’s characteristics were balanced between Gem (n = 49) and Obs (n = 48) group. KRAS, TP53, SMAD4 mutation was found in 73% (Gem/Obs n = 33/38), 59% (n = 28/29), 8% (n = 4/4) of patients. KRAS/SMAD4 mutation status was not associated with (treatment-related) survival. TP53 mutation was identified as a negative prognostic factor for untreated patients: hazard ratio (HR) for disease free-survival (DFS) TP53 mutant vs TP53 wildtype 2.90 (95% CI 1.55 -5.41). Furthermore, TP53 mutation was found to be a positive predictive factor for Gem: HR for DFS Gem vs Obs in TP53 wildtype patients was 0.87 (95% CI 0.46-1.66) in comparison to TP53 mutated patients with a HR of 0.22 (95% CI 0.12-0.39). Test of TP53-by-treatment-interaction was statistically significant; p = 0.002.


To the best of our knowledge, we present the first NGS data from a prospective clinical study in PDAC. In contrast to previous data, we could not identify KRAS or SMAD4 mutation as clinically relevant factors in primarily resectable PDAC. In CONKO-001, TP53 mutated patients had an unfavorable prognosis when randomized to Obs and profited strongly from adjuvant Gem, while adjuvant treatment did not significantly prolong DFS in TP53 wildtype patients.

Clinical trial identification


Legal entity responsible for the study

Charite Universitätsmedizin Berlin, CONKO-study group.


Charite Forschungsförderung, German Cancer Consortium (DKTK), Rahel-Hirsch grant.


M. Sinn: Honoraria, Advisory board: Baxalta. Research funding: Leo Pharma. Travel support: Amgen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.